San Diego, CA (PRWEB) March 09, 2013
Resource4thePeople announced today that its attorneys are now investigating claims from victims who allegedly may have suffered serious health problems as a result of their use of the popular blood thinner Pradaxa.
“Our lawyers are now actively investigating these claims and stand ready to provide consultations in which the legal options available to seek compensation in such cases can be provided to consumers,” said Resource4thePeople.
“We are now reviewing these claims as a result of the increasing number of inquiries from consumers about their legal rights in connection with serious health side effects such as internal bleeding that may have occurred as a result of using the medication Pradaxa."
Resource4thePeople notes that the increasing number of Pradaxa lawsuits being filed has caused the federal court system to create what is called a multidistrict litigation* in which cases from across the country are being consolidated.
"We will be informing consumers about whether they may be eligible to join in this multidistrict litigation which is now under the supervision of a single judge in Illinois," said Resource4thePeople.
In such cases victims are allowed to file allegations through which they may seek compensation for wrongful deaths, medical costs, pain and suffering and other expenses if they can prove their claims.
Multidistrict litigations are so designated by the federal court system when a large number of cases involving similar allegations are brought under the supervision of a single judge for pre-trial evidence gathering and other legal procedures.
That judge may set bellwether trials, in which both plaintiffs' and defendants' lawyers test the strengths and weaknesses of their cases, and may also eventually designated the litigation as a massive class-action.
"One of the inquiries we are repeatedly receiving is whether it is to late to file a lawsuit that could be part of this multi-district litigation," said Resource4thePeople. "The answer, in the overwhelming number of cases, is no."
"The federal judge in the case has not issued any order prohibiting additional claims being filed and, in his most recent ruling, found that plaintiffs' lawyers will be granted access to documents they were seeking, which means there will still be additional time before any trial is held."
U.S. District Court Judge David R. Herndon granted the request to victims’ lawyers in the multidistrict litigation seeking access to a case settled by Pradaxa manufacturer Boehringer Ingelheim last year.
Judge Herndon’s ruling against Boehringer Ingelheim involved a $95 million settlement over the company’s marketing campaign to promote Pradaxa.
The current litigation before Herndon involves allegations that Pradaxa can cause serious internal bleeding problems which can lead to heart attacks and brain hemorrhages.*
Herndon has scheduled the first bellwether trials in the Pradaxa litigation to start in August, 2014.
Boehringer Ingelheim has denied the claims that have been filed against them in the Pradaxa litigation, including allegations that the company was negligent by failing to adequately warn health care professionals and patients about bleeding side effects.*
According to allegations in the Pradaxa multi-district litigation, the drug was approved by the FDA in 2010 as an improvement over another blood-thinner, warfarin, for patients vulnerable to atrial fibrillation.
Plaintiffs in the Pradaxa multi-district litigation are claiming that in cases of internal bleeding there is an antidote for warfarin but there is no antidote for Pradaxa and that in some cases deaths have occurred.
There are currently over 150 lawsuits in the multi-district litigation before Judge Herndon and Bloomberg News recently reported that Pradaxa “has been linked to more than 500 U.S. deaths over a two-year period.”**
Bloomberg also reported that “Concerns about Pradaxa’s safety surfaced soon after U.S. doctors began prescribing it. FDA officials said they received reports of 542 deaths and 3,781 side-effect incidents tied to the drug in 2011.”**
Resource4thePeople also is advising consumers who may have been or are being treated with Pradaxa that the FDA recently issued a Drug Safety Communication warning that the medication should not be used in patients with mechanical prosthetic heart valves.***
In the communication the FDA also noted a previously released Drug Safety Communication about the risk of serious bleeding associated with the use of Pradaxa in patients with non-valvular atrial fibrillation, the population for which the drug is approved.